Kiniksa Pharmaceuticals International PLC
KNSAHealthcare|Drug Manufacturers - Specialty & Generic|UK
$63.44
-1.91 (-2.92%)
DCF (FCF)
$4.91
Tangible Book
$7.70
Graham Number
$12.49
Financials
Financial Snapshot
Market Cap
$4.88B
Enterprise Value
$459.1M
Revenue (TTM)
$754.0M
Net Income (TTM)
$73.1M
Cash & Equivalents
—
Net Cash/Share
$3.24
Free Cash Flow (TTM)
$164.2M
Operating CF (TTM)
$165.9M
Debt/Equity
0.02
Cash Runway & Burn Rate
Company is cash-flow positive.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $56.0M | $45.6M | $307.3M | $233.4M | $323.5M | $182.2M | $190.6M | $206.4M | $243.6M | $414.1M | $468.1M | |
| Operating Cash Flow | $-21.9M | $-50.2M | $-81.0M | $-158.4M | $-136.5M | $-126.3M | $5.8M | $13.3M | $25.7M | $138.0M | $165.9M | |
| Free Cash Flow | $-21.9M | $-50.3M | $-86.3M | $-161.6M | $-136.8M | $-146.7M | $5.7M | $13.2M | $25.4M | $136.4M | $164.2M | |
| Capital Expenditure | $-3.0K | $-69.0K | $-5.3M | $-3.2M | $-283.0K | $-20.4M | $-105.0K | $-130.0K | $-277.0K | $-1.6M | $-1.6M | |
| Financing Cash Flow | $42.5M | $39.9M | $346.7M | $84.1M | $227.1M | $5.9M | $2.5M | $1.5M | $12.3M | $33.0M | $36.3M |
R&D Spending
R&D (TTM)
$105.0M
R&D Intensity
13.9%
R&D Growth YoY
+8.4%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $38.5M | $220.2M | $270.3M | $423.2M | $677.6M | $754.0M | |
| R&D Expense | $17.4M | $56.4M | $86.6M | $135.0M | $112.0M | $99.3M | $65.5M | $76.1M | $111.6M | $96.9M | $105.0M | |
| R&D % of Revenue | — | — | — | — | — | 257.6% | 29.7% | 28.2% | 26.4% | 14.3% | 13.9% | |
| SG&A | $6.6M | $9.0M | $21.6M | $35.0M | $45.3M | $85.9M | $98.0M | $129.4M | $168.0M | $196.3M | $213.9M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $38.5M | $220.2M | $270.3M | $423.2M | $677.6M | $754.0M | |
| Cost of Goods Sold | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $9.9M | $47.0M | $89.9M | $189.2M | $307.2M | $341.9M | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $28.6M | $173.2M | $180.3M | $234.0M | $370.3M | $412.1M | |
| R&D | $17.4M | $56.4M | $86.6M | $135.0M | $112.0M | $99.3M | $65.5M | $76.1M | $111.6M | $96.9M | $105.0M | |
| SG&A | $6.6M | $9.0M | $21.6M | $35.0M | $45.3M | $85.9M | $98.0M | $129.4M | $168.0M | $196.3M | $213.9M | |
| Operating Income | $-24.0M | $-65.4M | $-108.2M | $-170.0M | $-157.4M | $-156.6M | $9.8M | $-25.2M | $-45.6M | $77.2M | $93.2M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | $-23.9M | $-64.9M | $-103.4M | $-163.9M | $-156.2M | $-156.5M | $11.0M | $-16.7M | $-36.2M | $88.9M | $106.0M | |
| Net Income | $-24.0M | $-64.9M | $-103.2M | $-161.9M | $-161.4M | $-157.9M | $183.4M | $14.1M | $-43.2M | $59.0M | $73.1M | |
| EPS (Diluted) | -0.74 | -2.00 | -3.49 | -2.99 | -2.61 | -2.30 | 2.60 | 0.20 | -0.60 | 0.75 | 0.90 | |
| EBITDA | $-24.0M | $-65.4M | $-107.9M | $-167.9M | $-155.0M | $-154.3M | $12.2M | $-22.9M | $-43.9M | $78.8M | $94.9M | |
| Shares Out. (M) | 32.47 | 32.47 | 29.55 | 54.05 | 61.84 | 68.58 | 70.42 | 71.92 | 71.42 | 78.98 | 82.41 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $56.0M | $45.6M | $72.0M | $46.9M | $114.0M | $122.5M | $122.7M | $108.0M | $183.6M | $165.6M | $190.0M | |
| Marketable Securities | $0.00 | $0.00 | $235.3M | $186.5M | $209.4M | $59.7M | $67.9M | $98.4M | $60.0M | $248.5M | $278.1M | |
| Total Current Assets | $56.3M | $47.1M | $313.8M | $241.6M | $333.2M | $196.4M | $243.1M | $276.3M | $331.8M | $527.2M | $594.2M | |
| Total Assets | $56.5M | $47.5M | $322.0M | $254.5M | $349.5M | $232.8M | $459.7M | $526.3M | $580.6M | $763.6M | $825.3M | |
| Total Current Liabilities | $2.3M | $17.4M | $42.6M | $27.8M | $31.8M | $44.8M | $47.1M | $63.7M | $100.6M | $139.2M | $156.6M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $82.2M | $137.2M | $42.7M | $29.1M | $37.5M | $47.8M | $63.5M | $87.5M | $142.1M | $196.0M | $219.6M | |
| Stockholders' Equity | $-25.7M | $-89.7M | $279.3M | $225.4M | $311.9M | $185.0M | $396.1M | $438.8M | $438.4M | $567.6M | $605.7M | |
| Retained Earnings | $-26.1M | $-91.0M | $-194.2M | $-356.1M | $-517.5M | $-675.4M | $-492.0M | $-477.9M | $-521.1M | $-462.1M | $-439.5M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $-21.9M | $-50.2M | $-81.0M | $-158.4M | $-136.5M | $-126.3M | $5.8M | $13.3M | $25.7M | $138.0M | $165.9M | |
| Capital Expenditure | $-3.0K | $-69.0K | $-5.3M | $-3.2M | $-283.0K | $-20.4M | $-105.0K | $-130.0K | $-277.0K | $-1.6M | $-1.6M | |
| Free Cash Flow | $-21.9M | $-50.3M | $-86.3M | $-161.6M | $-136.8M | $-146.7M | $5.7M | $13.2M | $25.4M | $136.4M | $164.2M | |
| Investing Cash Flow | $-3.0K | $-69.0K | $-239.2M | $49.2M | $-23.4M | $128.6M | $-8.1M | $-29.6M | $37.7M | $-189.0M | $-169.4M | |
| Financing Cash Flow | $42.5M | $39.9M | $346.7M | $84.1M | $227.1M | $5.9M | $2.5M | $1.5M | $12.3M | $33.0M | $36.3M | |
| Issuance of Stock | $0.00 | $0.00 | $159.2M | $83.1M | $228.2M | $0.00 | $3.4M | $0.00 | $0.00 | $0.00 | $0.00 | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-901.0K | $-2.2M | $-5.0M | $-7.7M | $-7.6M | |
| Issuance of Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Payments of Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $368.0K | $897.0K | $5.7M | $15.1M | $20.9M | $25.2M | $25.1M | $27.1M | $30.7M | $37.0M | $39.3M | |
| Net Change in Cash | $20.6M | $-10.4M | $26.5M | $-25.0M | $67.1M | $8.2M | $245.0K | $-14.8M | $75.6M | $-18.0M | $32.8M |
Dilution Tracker
Shares outstanding grew 20.2% over 5 years — significant dilution
Shares Outstanding
82M
5-Year Share Growth
+20.2%
Stock Issuance (TTM)
$0.00
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 32.47 | 32.47 | 29.55 | 54.05 | 61.84 | 68.58 | 70.42 | 71.92 | 71.42 | 78.98 | 82.41 | |
| YoY Change % | — | 0.0% | -9.0% | 82.9% | 14.4% | 10.9% | 2.7% | 2.1% | -0.7% | 10.6% | 4.3% | |
| Stock Issuance | $0.00 | $0.00 | $159.2M | $83.1M | $228.2M | $0.00 | $3.4M | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-901.0K | $-2.2M | $-5.0M | $-7.7M | $-7.6M | |
| Stock Based Comp. | $368.0K | $897.0K | $5.7M | $15.1M | $20.9M | $25.2M | $25.1M | $27.1M | $30.7M | $37.0M | $39.3M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 74.2% | 78.7% | 66.7% | 55.3% | 54.7% | 54.6% | |
| Operating Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -406.4% | 4.4% | -9.3% | -10.8% | 11.4% | 12.4% | |
| Net Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -409.7% | 83.3% | 5.2% | -10.2% | 8.7% | 9.7% | |
| EBITDA Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -400.3% | 5.5% | -8.5% | -10.4% | 11.6% | 12.6% | |
| FCF Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -380.6% | 2.6% | 4.9% | 6.0% | 20.1% | 21.8% | |
| ROE % | 0.0% | 0.0% | -108.9% | -64.1% | -60.1% | -63.6% | 63.1% | 3.4% | -9.8% | 11.7% | 13.7% | |
| ROA % | -42.5% | -124.8% | -55.9% | -56.2% | -53.4% | -54.2% | 53.0% | 2.9% | -7.8% | 8.8% | 10.3% | |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - | - |
Valuation
P/E (TTM)70.49
Historical3.87 / 59.35 / 927.50
Industry Med.20.86
P/S6.79
Historical2.93 / 5.04 / 135.66
Industry Med.2.30
P/B8.03
Historical1.92 / 3.62 / 8.17
Industry Med.1.91
EV/EBITDA46.60
Historical-143.62 / -4.12 / 433.94
Industry Med.12.96
EV/Revenue5.86
Historical2.39 / 4.56 / 107.58
Industry Med.2.46
P/FCF31.28
Historical19.76 / 43.82 / 222.39
Industry Med.20.93
Intrinsic Value Models
DCF (FCF Based)
$4.91
Tangible Book
$7.70
Net Current Assets
$4.880
Graham Number
$12.49
Net-Net Working Capital
$3.94
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PE Ratio | N/A | N/A | At Loss | At Loss | At Loss | At Loss | 5.76 | 87.70 | At Loss | 55.00 | 70.49 | |
| PS Ratio | - | - | - | - | - | 20.94 | 4.79 | 4.67 | 3.34 | 4.81 | 6.79 | |
| PB Ratio | 0.00 | 0.00 | 4.98 | 2.70 | 3.86 | 4.39 | 2.64 | 2.82 | 3.27 | 5.54 | 8.03 | |
| EV/EBITDA | 0.00 | 0.00 | -10.04 | -2.24 | -5.74 | -4.13 | 70.59 | -45.58 | -27.34 | 34.81 | 46.60 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 16.52 | 3.90 | 3.85 | 2.84 | 4.05 | 5.86 |
Analyst Estimates & Quality
Altman Z-Score
14.56
Safe
Piotroski F-Score
8
Strong
Beneish M-Score
-3.29
Unlikely Manipulator
Forward Estimates
| Metric | Current Year | Next Year | 2 Years Out |
|---|---|---|---|
| Revenue | $940.1M | $1,133.8M | $1,279.8M |
| Net Income | $108.4M | $155.1M | $207.9M |
| EPS | 1.18 | 2.15 | 3.12 |
| Book Value per Share | 10.05 | 13.37 | 0.00 |
| Operating Cash Flow per Share | -1.37 | 6.30 | 0.00 |
| Operating CF | $-112.90M | $519.18M | $0.00M |
Dividends
Revenue Segments
By Business
| Segment | 2025 |
|---|---|
| Product revenue, net | $677.6M |
By Geography
| Segment | 2025 |
|---|---|
| United States | $676.8M |
| United Kingdom | $814.0K |